samedan logo

 
 
spacer
home > pmps > summer 2008 > rfid to the rescue
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

RFID to the Rescue

During the development process of new therapeutic approaches, multi-phase clinical research studies (clinical trials) are the last hurdle to overcome. Hence clinical trials represent one of the crucial steps in the development of a new drug. In view of increasing competition, rising cost pressures and, above all, the need to bring new products to market as quickly as possible, the current process of clinical trial supply management harbours inefficiencies, which can be eliminated by innovative RFID-based technologies.

‘TIME TO MARKET’ IS CRUCIAL

The total costs of developing a new drug or treatment up to the point of approval can amount to as much as US$ 1 billion. Typically, a new drug will have been subjected to around 10 years of stringent preclinical testing before entering the first of a total of three clinical trial phases. Nonetheless, according to information published by the FDA in 2004, a new drug has merely an eight per cent chance of achieving final approval and thus being brought to market. One of the reasons for this is the fact that results obtained in animal tests can be applied to humans only to a limited extent: around 90 per cent of substances found to be safe with lab animals fail the test of subsequent clinical trials on humans.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.


spacer
Guido Moosmann is Business Development Director RFID at Schreiner MediPharm, one of the major divisions of Schreiner Group based in Oberschleissheim near Munich, Germany. Guido has extensive academic and industry experience in the field of RFID technologies. He is the author and co-author of various studies and books on source tagging and RFID standards.
spacer
Guido Moosmann
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

LPS Industries Announces New Cleanroom Certification with State-of-the-Art Equipment Technology

Moonachie, NJ -- (ReleaseWire) -- 06/02/2021 -- LPS Industries, Moonachie NJ, (www.lpsind.com), a vertically integrated flexible packaging manufacturer, announced the certification of its new Class 100,000 cleanroom. Madeleine D. Robinson, CEO of LPS Industries, stated, "We're excited to announce our brand-new Class 100,000 certified cleanroom facility, providing unprinted and custom printed flexible packaging roll stock for the food and medical markets. These customers must meet highly exacting standards, and this cleanroom ensures that we can help them achieve the quality required."
More info >>

White Papers

Modifying MDI Canister Surfaces to Improve Drug Stability & Drug Delivery

Presspart Manufacturing Ltd

Hydrofluoroalkane (HFA)-based propellants are widely used in modern metered-dose inhalers (MDIs), due to their lack hazardous and environmentally-damaging effects. However, an HFA's active pharmaceutical ingredient can interact with the canister substrate, causing deposition of the drug to the canister walls, or interact with the solution, causing degradation and resulting in increased impurity levels. Over the past few years, a number of surface coatings have been developed that can be applied to MDI canisters and valve components, to protect the contents from deposition and degradation. More recently, plasma processes have been developed to modify and improve the surface energy performance of a MDI canister. This approach has a number of advantages to alternative coatings but requires careful optimisation to ensure the highest quality finish and MDI performance. Richard Turner, Business Development Director, Presspart Manufacturing Ltd, explains.
More info >>

 
Industry Events

A Magic Triangle: Practical insights into lactose-based DPI formulations

30 June 2021, Online webinar

Three leading companies with complementary areas of expertise have joined forces to conduct a unique multidisciplinary study into lactose-based DPI formulations including magnesium stearate. Their findings will give generic players a head start in the development process so that they can tap into this rapidly growing market. Lactose specialist DFE Pharma, powder processing technology manufacturer Hosokawa Micron and machine-building expert Harro Hoefliger will be presenting the key insights from their research to interested parties during a joint webinar on the 30th of June.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement